Clinical Trials 下面列出了当前开展的临床试验。512 研究 Cancer (仅限开放研究). 根据地点、状态和其他条件对此研究列表进行过滤。 A Study to Evaluate the Impact of Non-invasive Tests for Bladder Cancer Rochester, Minn. Levels of bladder cancer-derived extracellular vesicles become undetectable after radical cystectomy in patients with localized bladder cancer. This study hopes to determine the levels of bladder cancer-derived extracellular vesicles pre- and post-RC. Perfusion MRI for Therapy Response Assessment in Brain Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to improve patient care by optimizing and measuring magnetic resonance imaging methods for the early detection of brain cancer response to therapy. A Registry for the Collection of Biological and Clinical Data for Studies of Immune System Related Blood Disorders Rochester, Minn. The purpose of this study is to develop and maintain a registry of clinical data and biological specimens from patients with immune system related blood disorders, for use in future studies of disease source, diagnosis, treatment, and prognosis. A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the effectiveness and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following definitive platinum-based concurrent chemoradiation therapy (cCRT). A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements. Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary goal of this study is to determine the impact of standard of care therapies for TCR MM, in a real-world setting, on patient-reported symptoms, functioning, and QoL, measured prospectively using questionnaires. The secondary goal is to asses clinical endopoints associated with standard of care therapies for TCR MM, in a real-world setting during 12 months of observation. VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary objectie of Safety Run-In Cohort (Cohort 1) is to evaluate the safety and tolerability of multiple intratumoral injections (IT) of VG161 at the recommendated Phase 2 Dose (RP2D) in patients with HCC and ICC who have either disease progression or intolerable toxicity after the standard treatments. The primary objective of HCC Cohort (Cohort 2) is to evaluate the efficacy of multiple IT injections of VG161 in patients with hepatocellular carcinoma (HCC). The primary objective of ICC Cohort (Cohort 3) is to evaluate the efficacy of multiple IT injections of VG161 in patients with intrahepatic cholangiocarcinoma. Clinical and Molecular Characteristics of Histiocytic Disorders Rochester, Minn. The purpose of this study is to assess the presence of various molecular markers in histiocytic disorders. In addition to this, to review clinical records of the patients with these disorders to assess the role of the molecular markers in patient outcomes. Mayo Clinic Cancer Center Neuro-Oncology Program Registry and Biobank for the Study of Nervous System Tumors Rochester, Minn. Biospecimen banks are a modern attempt to centralize collections of human blood and tissue samples along with health information and personal history. The Neuro-Oncology Program Registry and Biobank will be used for research purposes to increase our understanding of nervous system tumors. Breast MR Rochester, Minn. The purpose of this study is to examine the capability of contrast enhanced breast PCD-CT in staging breast cancer within the breasts and regional nodes of human subjects. Developing and using a PCD-CT imaging technique and postprocessing algorithms, dedicated for breast cancer detection. Cell Saver During Tumor Resection Rochester, Minn. The aims of this study are to investigate the presence of tumor cells after filtration of autologous blood products by intraoperative cell saver, and to demonstrate the feasibility of intraoperative blood salvage during intralesional tumor resection. Intraoperative blood salvage is a relatively safe and cost-effective alternative to allogeneic blood transfusion during procedures with large volume blood loss. Salvaged blood products are washed and filtered before reinfusion into the patient. Given the theoretical risk of systemically re-infusing samples contaminated with tumor cells, many surgeons refrain from using intraoperative blood salvage. Aside from a few small studies, there is a paucity of data on the ability of leukocyte reduction filters to remove tumor cells from salvaged blood products. Additionally, no studies to date have investigated this during intralesional tumor resections. Pagination 临床研究 PrevPrevious Page Go to page 3838 Go to page 3939 Go to page 4040 Go to page 4141 Go to page 4242 NextNext Page 医疗专业人员 Cancer clinical-trials